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Abstract 
Thymidine monophosphate kinase of Mycobacterium tuberculosis represents an attractive 
target for selectively blocking the bacterial DNA synthesis. Hereby, we report on the 
discovery of a novel class of bicyclic nucleosides (10 and 11) and one dinucleoside (12), 
belonging to the most selective inhibitors of TMPKmt discovered so far. 
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Introduction 
The appearance of multiple drug-resistant strains of Mycobacterium tuberculosis and the 
synergism between HIV and M. tuberculosis infection has caused a steeply rising incidence of 
tuberculosis during the last decades. This has made the development of new anti-tuberculosis 
agents, preferably acting on novel targets, a research priority for many health organizations.1 
M. tuberculosis thymidine monophosphate kinase (TMPKmt) recently emerged as a 
potentially attractive target for the design of a novel class of anti-tuberculosis agents.2  
TMPK catalyses the -phosphate transfer from ATP to thymidine monophosphate (dTMP) in 
the presence of Mg2+, yielding thymidine diphosphate (dTDP) and ADP.3 Because TMPK is 
essential for thymidine triphosphate (dTTP) synthesis and in view of its low (22%) sequence 
identity with the human isozyme (TMPKh),2 it represents an attractive target for selectively 
inhibiting mycobacterial DNA synthesis. Recently, the X-ray structure of TMPKmt was 
solved at 1.95Å as a complex with dTMP,4 allowing structure-based design of TMPKmt 
ligands. 
A series of 2'-, 3'- and 5-modified nucleosides and nucleotides was tested for their affinities 
with respect to TMPKmt.5,6,7,8 The results showed that, in general, nucleosides and their 
corresponding 5'-O-monophosphate esters were nearly equivalent inhibitors of TMPKmt. The 
low permeability of the cell wall for phosphorylated compounds (i.e. nucleotides) prompted 
us to focus on nucleosides as new drug leads. Recently, we reported a series of 3'-C-branched 
chain nucleosides and nucleotides that exhibit micromolar inhibitory activity against 
TMPKmt.9 The introduction of 3'-CH2OH, 3'-CH2NH2, 3'-CH2N3 and 3'-CH2F substituents 
was aimed at occupying a cavity in the enzyme near the 3'-position. Biological results and 
modeling confirmed this hypothesis. Modeling also indicated that these nucleosides bind to 
TMPKmt in the (N) (northern, 2'-exo-3'-endo) conformation dTMP, in contrast, binds to 
TMPKmt in the (S) (southern, 2'-endo, 3'-exo) conformation. This N-type sugar pucker 
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enables interactions between the 6'-substituent and Asp9.9 From this series of 3’-branched 
chain derivatives, 1-3-C-(azidomethyl)-2,3-dideoxy--D-threo-pentofuranosylthymine (1) 
emerged as a promising lead for further research, since it combines a low Ki-value with a 
favourable selectivity profile for TMPKmt versus TMPKh (Table 1). Moreover, 
conformational analysis of a series of 2'- and 3'-modified nucleosides showed that the 
presence of a halogen at the -face of the 2'-position, especially a 2'-fluorine, biases the sugar 
pucker of thymidine analogues strongly towards the (N) conformation.10 Based on these 
results and the high affinities of 2'-halogeno substituted nucleotides for TMPKmt5 (3 and 4, 
Table 1), it was considered interesting to combine a 2'-chlorine or a 2'-fluorine substituent 
with a 3'-aminomethyl or a 3'-azidomethyl group (5-8).9 In an attempt to supersede the good 
affinities of the 3'-C-branched-chain nucleosides, we also further explored the enzyme cavity 
near the 3'-position with alternative nitrogen containing substituents. 
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Results and Discussion  
Chemistry  
The synthesis of 5-9 started from 14 (obtained from 1,2-O-isopropylidene--D-xylofuranose 
in 11 steps11) (Scheme 1). After protection of the 5'-hydroxyl group, 15 was converted into 
anhydronucleoside 16 upon treatment with trifluoromethanesulfonyl chloride and DMAP.12 
Opening of the anhydro ring with HCl in dioxane yielded 5, the 2'--chloro analogue of 1.13 
The corresponding 2'-fluoro derivative 7 was obtained via formation of ara-nucleoside 17 
from 16 with NaOH,14 followed by fluorination with DAST15 and removal of the trityl 
protective group. Reduction of 5 and 7 with Ph3P and NH3 yielded the corresponding 3'-
amino analogues 6 and 8, respectively.11 Due to unwanted intramolecular attack of the 2-
carbonyl of thymine on the 5'-O-diethylaminosulphur difluoride intermediate, reaction of 7 
with DAST afforded 9 in low yield. 
In an attempt to prepare intermediate 20 for further derivatisation, the 5'-hydroxyl group of 14 
was first protected as t-butyldimethylsilyl ether 18 (Scheme 2). After esterification of the 2'-
hydroxyl with phenylchlorothionocarbonate (→19),11 however, attempted simultaneous 
reduction of the azido function and Barton deoxygenation at the 2’-position to give 20 failed. 
Instead three peculiar nucleoside analogues 21, 22 and 23 were formed. In a similar attempt, 
Robins et al. found that, apart from a low yield of the desired aminonucleoside, Barton 
deoxygenation of an azide in the presence of a phenoxythiocarbonyl ester led to some 
uncharacterised byproducts.16 Compounds 21 and 22 represent a novel class of bicyclic 
nucleoside analogues. 
The formation of carbamates through reaction of thioacids with azides has recently been 
studied by Shangguan et al.17 A mechanism is proposed in which the three nitrogens of the 
azide take part in formation of the carbamate. However, since access to the thiocarbamate 
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cannot be explained this way, it is suggested that a radical intermediate of the reduction of the 
azide interacts with a radical resulting from attack of a tributyltin radical on the thioester.  
Another surprising byproduct of this radical-mediated reduction is dinucleoside 23. Most 
probably, the ureido moiety of this dimer is formed through attack of the 6'-amines (resulting 
from reduction of the 6'-azide of 19) on the carbonoxysulfide, arising from decomposition of 
the 2'-phenylthionocarbonate ester.18 
The TBDMS-protective groups of 21, 22 and 23 were removed with TBAF in THF and the 
free nucleosides (10, 11 and 12) were tested for their affinity for TMPKmt. 
In view of the interesting biological properties of 10 (see below), a more efficient way for its 
synthesis was desirable. Tritylation of the 5'-hydroxyl of 14, followed by reduction of the 6'-
azido group (→24), treatment with thiocarbonyldiimidazole, and subsequent acidic removal 
of the 5'-trityl group afforded 10 in 62% overall yield. Likewise, 11 can be obtained by using 
carbonyldiimidazole. 
Conformational analysis 
Conformational analysis was performed for compounds 6 and 7. Based on the large vicinal 
‘pseudoaxial-axial’ coupling between 3’-H and 4’-H (3J3',4’ = 10.5 Hz) and on the very small 
coupling between 2’-H and 1’-H  ( 3J1',2'  0.0 Hz), we can conclude that in solution both 
compounds exist almost completely in the N-conformation (3’-endo-2’-exo-twist 
conformation). Indeed, it is accepted that the percentage N- or S-conformer can be estimated 
by multiplying 3J3',4 and 3J1',2' by a factor 10 respectively.19 The finding that the 3’--CH2X 
group apparently drives the pseudorotational N⇆S equilibrium towards the N-conformation 
even with a chlorine or fluorine substituent at the 2’-position, is completely in agreement with 
the observation of Plavec et al.20 They also found a predominant N-conformation for their 
branched chain 3’-CH2OH-2’,3’-dideoxy-D-erythro-cytidine derivatives.  
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Biological activity 
All nucleosides were tested for their affinity for TMPKmt (Table 1) via a reported 
spectrometric assay.21 The affinities of most 2'-halo substitued nucleosides were not as 
expected. In 5-8, the introduction of the 2'-halogen led to a drastic decrease in affinity 
compared to the corresponding 2'-deoxynucleosides. Due to the presence of the 2'-fluorine, 8 
showed no inhibition of the enzyme at 1 mM . Docking suggested that instead of enhancing 
the (N) conformation, necessary for optimal interaction between Asp9 and the 3'-substituent, 
the 2'-halogens compete with the 3'-substituents for the same binding pocket,5 thereby 
abolishing the affinity for the enzyme. Remarkably, introduction of a 5'-fluorine slightly  
increases the affinity of 7 (Ki of 9 = 80 M).  
Compounds 10, 11 and 12 were, likewise, assayed for their affinity for TMPKmt. 
Unexpectedly, these compounds are among the highest affinity inhibitors for TMPKmt found 
so far. Due to the lack of a binding site for a second nucleoside at the 3’-position, the Ki-value 
of 12 (37 M) was most unexpected. A modeling experiment in GOLD showed that the sugar 
ring of the first monomer I binds the dTMP-pocket upside down, which enables hydrogen 
bonding of its 5'-hydroxyl with Asp9 (Figure 1). This binding mode permits the sugar ring of 
the second monomer (II) to be directed towards the outside of the enzyme, where normally 
the phosphoryl donor binds. This orientation is the only feasible conformer to have 12 
accommodated by the enzyme. The thymine base of II undergoes only few hydrophobic 
interactions with Phe36, Ala35 and Tyr39. Comparison with the binding positions of ATP4 
and bisubstrate inhibitor Ap5T22 showed that nucleoside II does not bind to the pocket where 
adenosine normally resides. Instead, it is buried deeper in the enzyme. Competition 
experiments, performed with dTMP and ATP showed that this dinucleoside is not only a 
competitive inhibitor for dTMP but also for ATP (at 0.2 mM dTMP, 12 is a competitive 
inhibitor for ATP with a Ki-value of 0.65 mM). These results are in agreement with the 
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binding mode proposed in Figure 1. The fact that these two nucleosides in 12 are bound via 
their 3'-positions makes it a unique example of a bisubstrate inhibitor, thereby paving the way 
for the design of much larger molecules as inhibitors for TMPKmt than explored thus far. 
The observed affinity of -nucleoside 13 (an undesired anomer formed during the synthesis 
of 19) could further confirm the postulated binding mode of monomer I. A similar sugar 
orientation would position the thymine base ideally for stacking with Phe70. Indeed, with a 
Ki-value of 29 M, this compound proves to be a good inhibitor of TMPKmt. Docking in 
GOLD showed a similar binding mode of the sugar ring, rendering stacking interaction with 
Phe70 possible (Figure 2). The 5'-hydroxyl interacts through hydrogen bonding with Asp9 
and the azido group, lying in the cavity where normally the 5'-phosphoryl of dTMP resides, is 
engaged in a polar interaction with Arg95 and Asp9. This exceptional flexibility of TMPKmt 
towards the orientation of the sugar ring is of great interest for further inhibitor design. 
Bicyclic nucleosides 10 and 11 showed excellent binding affinities. The Ki-value of 3.5 M of 
10 is lower than  the Km-value of the natural substrate (4.5 M). Compound 10 was modelled 
into the crystal structure of TMPKmt (Figure 3).4 The six-membered ring, fused to the the C-
2', C-3'-bond of the sugar, apparently forces the 6'-nitrogen into the most appropriate position 
for interaction with the Asp9 residue in the enzyme cavity. The sulphur atom, in its turn, 
undergoes hydrophobic interactions with Tyr103 and Tyr165 residues. When the sulphur 
atom in 10 is replaced by a smaller oxygen in 11, the cavity near the 3'-position is filled less 
efficiently, which is reflected in the somewhat lower affinity of 11. The functionalities of the 
extra ring convincingly contribute to the high affinity interactions with the biological target.  
The highest affinity inhibitors of this series were tested for their affinity for TMPKh. The low 
affinities of 12 and 13 for the human enzyme indicate that the flexibility towards the 
orientation of the sugar ring is unique for TMPKmt. Most interesting, however, is compound 
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10, with a selectivity index (Ki TMPKh/ Ki TMPKmt) of 200, superseding 1 not only in 
affinity, but also in selectivity.  
Compounds 1 and 2, which were described earlier,9 did not show any significant inhibition of 
M. tuberculosis at a concentration of 6.25 g/ml. This is not surprising since this 
concentration is lower then the Ki-values of these inhibitors for TMPKmt. Therefore, 
inhibitors with superior Ki-values are indispensable to provide novel antimycobacterial leads. 
The discovery of the bicyclic analogues 10 and 11 is an important step towards this goal. 
Conclusions 
In inhibitor design the binding pocket of the nucleoside in nucleoside and nucleotide 
metabolizing enzymes is generally explored by introducing small modifications to the 
substrate. In the present example, however, a variety of sugar modified thymidine analogues 
have been discovered with apparently different binding modes to TMPKmt involving Asp9, 
Tyr103 and Phe70 as common amino acids to anchor the inhibitors. These molecules may 
function as leads for further drug design, increasing considerably the variety of nucleoside 
analogues that may be considered for further synthesis. Of particular importance is the 
bicyclic nucleoside 10 with a Ki for TMPKmt of 3.5 M and a SI of 200, which will be used 
as starting compound to increase further affinity for TMPKmt. 
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Experimental Section 
(1) Spectrophotometric binding assay. 
TMPKmt and TMPKh activities were determined using the coupled spectrophotometric assay 
described by Blondin et al.21 at 334 nm in an Eppendorf ECOM 6122 photometer. The 
reaction medium (0.5 mL final volume) contained 50 mM Tris-HCl pH 7.4, 50 mM KCl, 2 
mM MgCl2, 0.2 mM NADH, 1 mM phosphoenol pyruvate and 2 units each of lactate 
dehydrogenase, pyruvate kinase and nucleoside diphosphate kinase. The concentrations of 
ATP and dTMP were kept constant at 0.5 mM and 0.05 mM respectively, whereas the 
concentrations of analogues varied between 0.1 and 2.5 mM. 
(2) Inhibition assay of M. tuberculosis. 
The screening was conducted at 6.25 g/ml against Mycobacterium tuberculosis H37Rv 
(ATCC 27294) in BACTEC 12B medium using a broth microdilution assay, the Microplate 
Assay (MABA).23 
(3) Modeling: docking experiments using GOLD. 
The X-ray structure published by de la Sierra et al.4 (pdb entry 1G3U) was used in all docking 
experiments. Water molecules and sulphate counter ions were removed. The Mg2+ was 
considered as being part of the enzyme. Explicit hydrogen atoms were added to the enzyme 
and inhibitor structures using Reduce.24 The inhibitor structures 10, 12 and 13 were created 
using Macromodel 5.0,25 based on the dTMP substrate from pdb entry 1G3U. Their geometry 
was optimized in the AM1 force field using Mopac6.0.26 PDB files were then converted to 
mol2 files using Babel.27 The position of atom C1' in the dTMP ligand in the pdb file 1G3U 
was used as the center of a 20 Å docking sphere. Default settings were used in Gold for all 
dockings.28,29 The structures in the top 50 of the docking scores were retained for visual 
inspection and comparison with published X-ray structures 1G3U 4 and 1MRN.22 Criteria for 
selection were the same position (but not necessarily the same orientation) of the base, the 
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nonbonded interactions as calculated by Ligplot30 and HBPLUS.31 Figures 1-3 were generated 
using Molscript.32 
(4) Synthesis. General. NMR spectra were obtained with a Varian Mercury 300 or 500 
spectrometer. Chemical shifts are given in ppm () relative to residual solvent peak of 
DMSO-d6 (2.5 ppm). All signals assigned to amino and hydroxyl groups were exchangeable 
with D2O. Mass spectra and exact mass measurements were performed on a 
quadrupole/orthogonal-acceleration time-of-flight (Q/oaTOF) tandem mass spectrometer 
(qTof 2, Micromass, Manchester, UK) equipped with a standard electrospray ionisation (ESI) 
interface. Samples were infused in a 2-propanol:water (1:1) mixture at 3 µL/min. Precoated 
Merck silica gel F254 plates were used for TLC and spots were examined under UV light at 
254 nm and revealed by sulfuric acid-anisaldehyde spray. Column chromatography was 
performed on Uetikon silica (0.2-0.06 mm).  
Anhydrous solvents were obtained as follows: THF was distilled from sodium/benzophenone; 
pyridine was refluxed overnight over potassium hydroxide and distilled; dichloromethane, 
dichloroethane and toluene were stored over calcium hydride, refluxed, and distilled; DMF 
was stored over Linde 4 Å molecular sieves, followed by distillation under reduced pressure.  
1-[3-Azidomethyl-3-deoxy-5-O-trityl--D-ribofuranosylthymine (15). To a solution of 
1411 (700 mg, 2.35 mmol) in pyridine (6 mL) containing DMAP (345 mg, 2.82 mmol) trityl 
chloride (786 mg, 2.82 mmol) was added in different portions. The mixture was heated to 65 
°C and stirred overnight. Then it was diluted with CH2Cl2 (50 mL), washed with saturated 
aqueous NaHCO3 (50 mL), and dried over anhydrous MgSO4. The solvent was removed 
under diminished pressure and the resulting residue was purified by column chromatography 
(CH2Cl2-MeOH, 98:2) affording 15 (1.15 g, 92%) as a white foam. 1H NMR (300 MHz, 
DMSO-d6):  1.42 (3H, d, J = 1.2 Hz, 5-CH3), 2.50 (1H, m, H-3'), 3.13-3.22 (2H, m, H-5' and 
H-6'), 3.37 (1H, dd, J = 1.8 Hz and 10.8 Hz, H-5''), 3.60 (1H, dd, J = 6.9 and 12.6 Hz, H-6''), 
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4.03 (1H, ddd, J = 2.1, 3.9 and 9.0 Hz, H-4'), 4.32 (1H, dd, J = 2.1 and 6.0 Hz, H-2'), 5.68 
(1H, d, J = 2.4 Hz, 2'-OH), 5.86 (1H, d, J = 5.4 Hz, H-1'), 7.35 (15H, m, arom H), 7.55 (1H, 
d, H-6); HRMS (ESI-MS) for C30H29N5O5Na M + Na+: found, 562.2067; calcd, 562.2066.  
2,2'-Anhydro-1-(3-azidomethyl-3-deoxy-5-O-trityl--D-arabinofuranosyl)thymine (16). 
A solution of 15 (940 mg, 1.74 mmol) and DMAP (854 mg, 7.00 mmol) in CH2Cl2 (17 mL) 
was stirred at room temperature. After stirring for 30 minutes trifluoromethanesulfonyl 
chloride (0.37 mL, 3.50 mmol) was added to the cooled (4 °C) solution. After further stirring 
for 3h at the same temperature, the reaction was quenched with water (20 mL) and extracted 
with CH2Cl2 (20 mL). The organic layer was successively washed with an aqueous saturated 
solution of Na2CO3 (20 mL), dried over anhydrous MgSO4 and evaporated under reduced 
pressure. The obtained residue was purified by column chromatography (CH2Cl2-MeOH, 
97:3) to yield 16 (743 mg, 82 %) as a white foam.1H NMR (300 MHz, DMSO-d6):  1.76 
(3H, d, 5-CH3), 2.66 (1H, m, H-3'), 2.82 (1H, dd, J = 6.6 and 10.2 Hz, H-5'), 3.01 (1H, dd, J = 
3.9 and 10.5 Hz, H-5''), 5.57 (2H, m, H-6'/6”), 5.21 (1H, m, H-4'), 5.27 (1H, dd, J = 2.1 and 
5.4 Hz, H-2'), 6.20 (1H, d, J = 6.0 Hz, H-1'), 7.22 (15H, m, arom H), 7.80 (1H, d, J = 1.5 Hz, 
H-6); HRMS (ESI-MS) for C30H28N5O4 M + H+: found, 522.2138; calcd, 522.2141. 
1-(3-Azidomethyl-2-chloro-2,3-dideoxy--D-ribofuranosyl)thymine (5). An ice-cooled 
suspension of 16 (220 mg, 0.42 mmol) in dry dioxane (50 mL) was saturated with anhydrous 
hydrogen chloride. The mixture was heated in a sealed tube at 75-80 °C for 24 h. After 
cooling, the solution was concentrated and the obtained residue purified by column 
chromatography (CH2Cl2-MeOH, 97:3), yielding 5 (90 mg, 71%) as a white foam. 1H NMR 
(300 MHz, DMSO-d6):  1.74 (3H, s, 5-CH3), 2.72 (1H, m, H-3'), 3.57 (3H, m, H-5' and H-
6'/6”), 3.84 (1H, m, H-5''), 4.01 (1H, app d, J3', 4' = 9.9 Hz, H-4'), 4.81 (1H, app d, J2', 3' = 5.4 
Hz, H-2'), 5.36 (1H, t, J = 4.8 Hz, 5'-OH), 5.89 (1H, d, J = 1.5 Hz, H-1'), 8.01 (1H, d, H-6), 
11.30 (1H, s, NH); 13C NMR (75 MHz, DMSO-d6):  12.96 (5-CH3), C-3’hidden by DMSO 
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signal, 48.73 (C-6'), 60.15 (C-5'), 65.32 (C-2'), 83.57 (C-4'), 91.36 (C-1'), 109.07 (C-5), 
136.06 (C-6), 151.04 (C-2), 162.12 (C-4); HRMS (ESI-MS) for C11H14ClN5O4Na M + Na+: 
found, 338.0615; calcd, 338.0632. Anal. (C11H14ClN5O4) C, H, N. 
1-[3-Aminomethyl-2-chloro-2,3-dideoxy--D-ribofuranosyl]thymine (6). Compound 5 (60 
mg, 0.20 mmol) and triphenylphosphine (87 mg, 0.33 mmol) were dissolved in pyridine (3 
mL) and stirred at room temperature. After 1h, concentrated NH4OH (2 mL) was added and 
the solution was allowed to stir for an additional 6.5 h. Pyridine was removed at reduced 
pressure, water (50 mL) was added and the unreacted triphenylphosphine and 
triphenylphosphine oxide were removed by filtration. The filtrate was extracted with toluene 
and the water layer was evaporated under reduced pressure to give a syrup, which was 
purified by column chromatography  (CH2Cl2-MeOH-7N NH3 in MeOH, 90:7.5:2.5) to yield 
6 (42 mg, 72 %) as a white foam. 1H NMR (500 MHz, DMSO-d6): δ  1.75 (3H, d, J = 1.2 Hz, 
5-CH3), 2.80 (1H, app sext, J = 5.4 Hz (5x), H-3'), 2.97 (2H, d, J6'A/B,3' = 6.6 Hz, H-6'A+B), 
3.31 (br, 5'-OH, NH2, N3-H), 3.73 (1H, dd, J5'B,4' = 2.0 Hz, J5'B,5'A = 13.2 Hz, H-5'B), 3.89 (1H, 
dd, J5'A,4' = 2.4 Hz, J5'A,5'B = 13.2 Hz, H-5'A), 4.04 (1H, dt, J4',3' = 10.5 Hz,  J4',5' = 2.2 Hz (2x), 
H-4'), 4.90 (1H, d, J2',3' = 4.6 Hz, H-2'), 5.87 (1H, s, H-1'), 8.14 (1H, q, J = 1.2 Hz, H-6) ppm; 
13C NMR (75 MHz, DMSO-d6):  12.93 (5-CH3), 38.06 (C-3'), 42.90 (C-6'), 60.04 (C-5'), 
66.39 (C-2', 84.06 (C-4'), 91.53 (C-1'), 108.90 (C-5), 136.06 (C-6), 150.89 (C-4), 164.47 (C-
2); HRMS (ESI-MS) for C11H17ClN3O4 M + H+: found, 290.0911; calcd, 290.0907. Anal. 
(C11H16ClN3O4.2H2O) C, H, N; N: calcd, 12.90; found, 11.81. 
1-(3-Azidomethyl-3-deoxy-5-O-trityl--D-arabinofuranosyl)thymine (17). A mixture of 16 
(590 mg, 1.13 mmol), 1N NaOH (3.2 mL), dioxane (45 mL) and EtOH-H2O (1:1, 45 mL) was 
stirred at room temperature for 2h. The solution was neutralized with HOAc/EtOH (1:1, v/v) 
to pH 7. The resulting mixture was extracted with CH2Cl2 (100 mL) and the organic layer was 
dried over anhydrous MgSO4, evaporated under reduced pressure and purified by column 
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chromatography (CH2Cl2-MeOH, 90:10), yielding 17 (530 mg, 87 %) as a white foam. 1H 
NMR (300 MHz, DMSO-d6):  1.53 (3H, s, 5-CH3), 2.32 (1H, m, H-3'), 3.21-3.43 (3H, m, H-
5'/5'', H-6'), 3.56 (1H, dd, J = 5.7 and 12.6 Hz, H-6''), 3.80 (1H, m, H-4'), 4.11 (1H, t, J = 5.4 
Hz, H-2'), 5.60 (1H, d, J = 5.1 Hz, 2'-OH), 5.97 (1H, d, J = 5.7 Hz, H-1'), 7.32 (15H, m, arom 
H). 
1-(3-Azidomethyl-2,3-dideoxy-2-fluoro--D-ribofuranosyl)thymine (7). To a solution of 
17 (640 mg, 1.19 mmol) in toluene (12 mL) containing pyridine (1.2 mL), DAST (0.59 mL, 
4.42 mmol) was added and the mixture was stirred for 2 h at room temperature and then for 3 
h at 50 °C. The reaction was quenched with ice-water (50 mL) and extracted with CH2Cl2 (50 
mL). The organic layer was dried over anhydrous MgSO4, evaporated under reduced pressure 
and purified by column chromatography (CH2Cl2-MeOH, 97:3), yielding 1-[3-azidomethyl-
2,3-dideoxy-2-fluoro-5-O-trityl--D-ribofuranosyl]thymine (460 mg, 72 %) as a white foam. 
1H NMR (300 MHz, DMSO-d6):  1.45 (3H, s, 5-CH3), 2.85 (1H, m, J3', F = 33.0 Hz, H-3'), 
3.20 (4H, m, H-5'/5” and H-6'/6”), 4.11 (1H, app d, J4', F = 9.6 Hz, H-4'), 5.40 (1H, dd, J2', 3' = 
3.9 Hz, J2', F = 52.2 Hz, H-2'), 5.87 (1H, d, J1', F = 21.6 Hz, H-1'), 7.32 (15H, m, arom H), 7.55 
(1H, s, H-6); HRMS (ESI-MS) for C30H28FN5O4Na M + Na+: found, 564.2020; calcd, 
564.2023. 
The obtained foam was dissolved in 80% HOAc in H2O (7 mL). The mixture was heated to 
90°C during 1h. The solvent was removed under reduced pressure and the residue purified by 
column chromatography (CH2Cl2-MeOH, 90:10), yielding 10 (221 mg, 62% from 17) as a 
white foam. 1H NMR (500 MHz, DMSO-d6): δ  1.75 (3H, d, J = 1.2 Hz, 5-CH3), 2.64 (1H, 
ddddd, , J3',F = 33.1 Hz, J3',2' = 4.4 Hz, J3',6'B = 5.9 Hz, J3',6'A = 8.7 Hz, J3',4' = 10.5 Hz, H-3'), 
3.50 (1H, ddd, J6'B,F = 1.4 Hz, J6'B,3' = 6.0 Hz, J6'B,6'A = 12.7 Hz, H-6'B,), 3.57 (1H, dd, J6'A,3' = 
8.7 Hz, J6'A,6'B = 12.7 Hz, H-6'A), 3.61 (1H, ddd, J5'B,4' = 3.0 Hz, J5'B,OH = 4.9 Hz, J5'B,5'A = 12.7 
Hz, H-5'B), 3.84 (1H, ddd, H-5'A = 2.5 Hz, J5'A,OH = 5.6 Hz, J5'A,5'B = 12.7 Hz, J5'A,4'), 3.99 (1H, 
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dt, J4',3' = 10.5 Hz, J4',5'A/B = 2.7 Hz (2x), H-4'), 5.30 (1H, t, JOH,5'A/B = 5.25 Hz, 5'-OH), 5.32 
(1H, dd, J2',3' = 4.4 Hz, J2',F = 52.5 Hz, H-2'), 5.88 (1H, d, J1',F = 19.3 Hz, H-1'), 7.88 (1H, q,  J 
= 1.2 Hz, H-6), 11.34 (1H, s, N3-H) ppm; 13C NMR (125 MHz, DMSO-d6):   12.29 (5-CH3), 
40.53 (d, C-3', 2J3',F = 18.5 Hz), 46.13 (d, 3J6',F = 7.8 Hz, C-6'), 59.76 (C-5'), 82.83 (C-4'), 
88.80 (d, 2J1',F = 36.3 Hz, C-1'), 96.84 (d, 1J2',F = 181.6 Hz, C-2'), 108.73 (C-5), 136.03 (C-6), 
150.29 (C-2), 163.94 (C-4) ppm; 19F NMR (300 MHz, D2O):  -195.046; HRMS (ESI-MS) 
for C11H14FN5O4Na M + Na+: found, 322.0908; calcd, 322.092. Anal. (C11H14FN5O4) C, H, 
N. 
1-(3-Aminomethyl-2,3-dideoxy-2-fluoro--D-ribofuranosyl)thymine (8). This compound 
was synthesized from 7 (80 mg, 0.26 mmol) using the procedure described for the synthesis of 
6, yielding 54 mg (77 %) of amine 8 as a foam. 1H NMR (300 MHz, DMSO-d6):  1.73 (3H, 
s, 5-CH3), 2.30 (1H, m, J3', F = 34.2 Hz, H-3'), 2.57 (1H, m, H-6'), 2.76 (1H, m, H-6''), 3.62 
(1H, d, J = 12.0 Hz, H-5'), 3.79 (1H, d, H-5''), 3.89 (1H, app d, J4', F = 10.2 Hz, H-4'), 5.03 
(1H, br s, 5'-OH), 5.22 (1H, d, J2', F = 51.9 Hz, H-2'), 5.82 (1H, d, J1', F = 18.3 Hz, H-1'), 7.85 
(1H, s, H-6); 13C NMR (75 MHz, DMSO-d6):  12.95 (5-CH3), 36.95 (J = 7.7 Hz) and 44.76 
(J = 18 Hz) (C-3' and C-6'), 60.63 (C-5'), 84.41 (C-4'), 89.07 (C-1', J1', F = 36.3 Hz), 97.89 (C-
2', J2', F = 179.4 Hz), 109.21 (C-5), 136.43 (C-6), 150.79 (C-2), 164.51 (C-4); 19F NMR (300 
MHz, D2O):  195.70; HRMS (ESI-MS) for C11H17FN3O4 M + H+: found, 274.1191; 
calcd, 274.1202. Anal. (C11H16FN3O4.1/2H2O) C, H, N; N: calcd, 14.89; found, 13.61. 
1-(3-Azidomethyl-2,5-difluoro-2,3,5-trideoxy--D-ribofuranosyl)thymine (9). This 
compound was synthesized from 7 (66 mg, 0.22 mmol) using the procedure described for the 
synthesis of 7, to yield 12 mg (18 %) of 9. 1H NMR (300 MHz, DMSO-d6):  1.75 (3H, s, 5-
CH3), 2.67 (1H, m, J3', F = 24.0 Hz, H-3'), 3.60 (2H, m, H-6'/6”), 4.61 (1H, ddd, J5', 4' = 4.2 Hz, 
J5', 5'' = 10.8 Hz, J5', F = 49.5 Hz, H-5'), 4.80 (1H, dd, H-5''), 5.41 (1H, dd, J2', 3' = 4.8 Hz, J2', F = 
52.5 Hz, H-2'), 5.88 (1H, d, J1', F = 21.3 Hz, H-1'), 7.40 (1H, s, H-6); 13C NMR (75 MHz, 
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DMSO-d6):  12.87 (5-CH3), under DMSO signal (C-3'), 46.68 (C-6'), 81.10 (C-4', J4', F = 18.1 
Hz), 83.02 (C-5', J5', F = 170.0 Hz), 90.60 (C-1', J1', F = 38.0 Hz), 96.90 (C-2', J2', F = 181.2 Hz), 
110.01 (C-5), 136.81 (C-6), 150.87 (C-2), 164.52 (C-4); 19F NMR (300 MHz, D2O):  
194.04 and 228.74; HRMS (ESI-MS) for C11H13F2N5O3Na M + Na+: found, 324.0881; 
calcd, 324.0884. Anal. (C11H13F2N5O3) C, H, N. 
1-3-Aminomethyl-3-deoxy-5-O-(tert-butyldimethyl)silyl-2-O,6-N-(thiocarbonyl)--D-
ribofuranosylthymine (21), 1-(3-aminomethyl-2-O,6-N-carbonyl-3-deoxy-5-O-(tert-
butyldimethyl)silyl--D-ribofuranosyl)thymine (22) and 1,3-bis[(3R)-(3'-deoxy-5’-O-(tert-
butyldimethyl)silyl-thymidin-3'-yl)methyl]urea (23). To a solution of 1911 (460 mg, 0.84 
mmol) in toluene was added 2,2'-azobis(2-methylpropionitrile) (354 mg, 2.1 mmol) and tri-n-
butyltinhydride (0.48 g, 1.65 mmol) at 50-60 °C under N2. The reaction mixture was stirred at 
95-100 °C for 5h. The solvent was removed in vacuo and the residue was purified by silica 
gel column chromatography (CH2Cl2-MeOH, 99:1  95:5), affording produce 21 (0.16 
mmol, 20 %), 22 (17 %) and 23 (19 %) as white solids. 21: 1H NMR (300 MHz, DMSO-d6):  
0.00 (6H, s, (CH3)2Si), 0.80 (9H, s, C(CH3)3), 1.70 (3H, s, 5-CH3), 2.76 (1H, m, H-3'), 3.11 
(1H, d, H-6'), 3.39 (1H, dd, J6”, 3' = 5.70 Hz, J6”, 6’' = 13.5 Hz, H-6''), 3.86 (3H, m, H-4' and H-
5'/5”), 4.95 (1H, d, J2', 3' = 5.1 Hz, H-2'), 5.75 (1H, s, H-1'), 7.45 (1H, s, H-6), 9.81 (1H, s, 6’-
NH), 11.36 (1H, s, N(3)H); HRMS (ESI-MS) for C18H30N3O5SSi M + H+: found, 428.1675; 
calcd, 428.1675.  
22: 1H NMR (300 MHz, DMSO-d6):  0.00 (6H, s, (CH3)2Si), 0.81 (9H, s, C(CH3)3), 1.70 
(3H, s, 5-CH3), 2.61 (1H, m, H-3'), 3.07 (1H, br d, H-6'), 3.37 (1H, dd, J6”, 3’' = 5.7 Hz, J6”, 6’' = 
12.3 Hz, H-6''), 3.78 (1H, dd, J5', 4' = 3.6 Hz, J5', 5'' = 12.0 Hz, H-5'), 3.91 (1H, dd, H-5''), 3.98 
(1H, dt, J = 2.7 and 9.6 Hz, H-4'), 4.90 (1H, br d, J2', 3' = 5.7 Hz, H-2'), 5.70 (1H, d, J = 1.2 Hz, 
H-1'), 7.37 (1H, br s, 6'-NH), 7.44 (1H, d, = 1.2 Hz, H-6); HRMS (ESI-MS) for C18H30N3O6Si 
M + H+: found, 412.1897; calcd, 412.1903. 
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23: 1H NMR (300 MHz, DMSO-d6):  0.15 (12H, s, (CH3)2Si), 0.83 (18H, s, (CH3)3C), 1.73 
(6H, s, 5-CH3), 2.03 (4H, m, H-2'), 2.30 (2H, m, H-3'), 3.05 (4H, m, H-6'/6”), 3.71 (6H, m, H-
4' and H-5'/5”), 5.94 (2H, t, J = 5.4 Hz, H-1'), 6.01 (2H, t, 6'-NH), 7.46 (2H, d, J = 1.2 Hz, H-
6); HRMS (ESI-MS) for C35H60N6O9Si2Na M + Na+: found, 787.3970; calcd, 787.3858.  
1-3-Aminomethyl-3-deoxy-2-O,6-N-(thiocarbonyl)--D-ribofuranosylthymine (10) 
A solution of 21 (70 mg, 0.16 mmol) was treated with 5 equivalents TBAF in THF. After 1 
hour the mixture was evaporated to dryness and purified by column chromatography (CH2Cl2-
MeOH, 95:5), yielding 10 as a white powder (47 mg, 92%).1H NMR (300 MHz, DMSO-d6): 
 1.73 (3H, s, 5-CH3), 2.80 (1H, m, H-3'), 3.45 (1H, d, H-6'), 3.42 (1H, dd, J6”, 3' = 6.0 Hz, J6”, 
6’' = 14.1 Hz, H-6''), 3.66 (1H, br d, H-5'), 3.85 (1H, br d, J5”, 5’' = 12.6 Hz, H-5''), 3.92 (1H, m, 
H-4'), 4.95 (1H, d, J2', 3' = 5.0 Hz, H-2'), 5.34 (1H, t, 5'-OH), 5.82 (1H, s, H-1'), 7.97 (1H, s, H-
6), 9.83 (1H, br s, 6’-NH), 11.35 (1H, br s, N(3)H); 13C NMR (75 MHz, DMSO-d6):  12.89 
(5-CH3), 31.54 (C-3'), 37.18 (C-6'), 59.65 (C-5'), 82.57 (C-4'), 83.98 (C-2'), 89.28 (C-1'), 
109.30 (C-5), 136.84 (C-6), 150.84 (C-2), 164.43 (C-4), 184.48 (C=S); HRMS (ESI-MS) for 
C12H15N3O5SNa M + Na+: found, 336.0636; calcd, 336.0630. Anal. (C12H15N3O5S) C, H, N. 
1-(3-Aminomethyl-2-O,6-N-carbonyl-3-deoxy--D-ribofuranosyl)thymine (11) 
11 was prepared from 22 (60 mg, 0.15 mmol) using the procedure as described for the 
synthesis of 10, yielding 11 (39 mg, 90  %) as a white powder.1H NMR (300 MHz, DMSO-
d6):  1.74 (3H, s, 5-CH3), 2.66 (1H, m, H-3'), 3.13 (1H, m, H-6'), 3.42 (1H, dd, J6'', 3' = 5.4 
Hz, J6”, 6’' = 12.9 Hz, H-6''), 3.64 (1H, m, H-5'), 3.82 (1H, m, H-5''), 4.02 (1H, dt, J= 2.7 and 
10.2 Hz, H-4'), 4.90 (1H, d, J2', 3' = 5.4 Hz, H-2'), 5.31 (1H, t, J = 5.1 Hz, 5'-OH), 5.72 (1H, s, 
H-1'), 7.39 (1H, d, J = 3.0 Hz, H-6), 7.97 (1H, s, 6'-NH), 11.29 (1H, br s, N(3)H); 13C NMR 
(75 MHz, DMSO-d6):  12.88 (5-CH3), 32.44 (C-3'), 36.73 (C-6'), 59.94 (C-5'), 82.50 (C-4'), 
83.31 (C-2'), 89.83 (C-1'), 109.28 (C-5), 136.62 (C-6), 150.86 (C=O), 151.84 (C-2), 164.44 
 19
(C-4); HRMS (ESI-MS) for C12H15N3O6Na M + Na+: found, 320.0856; calcd, 320.0858. 
Anal. (C12H15N3O6) C, H, N.  
1,3-Bis[(3R)-(3'-deoxythymidin-3'-yl)methyl]urea (12) 
12 was prepared from 23 (120 mg, 0.16 mmol) using the procedure as described for the 
synthesis of 10, yielding 12 (80 mg, 93  %) as a white powder.1H NMR (300 MHz, DMSO-
d6):  1.75 (6H, s, 5-CH3), 2.04 (4H, m, H-2'), 2.33 (2H, m, H-3'), 3.08 (4H, m, H-6'/6”), 3.52 
(2H, dd, J = 4.5 and 12.6 Hz, H-5'), 3.66 (4H, m, H-4' and H-5”), 5.03 (2H, t, J = 5.1 Hz, 5'-
OH), 5.94 (2H, t, J = 6.6 Hz, H-1'), 6.00 (2H, t, J = 6.0 Hz, 6'-NH), 7.84 (2H, s, H-6); 13C 
NMR (75 MHz, DMSO-d6):  12.96 (5-CH3), 36.74 (C-2'), 38.97 and hidden by DMSO-
signal (C-3' and C-6'), 61.78 (C-5'), 84.58 (C-1' and C-4'), 109.30 (C-5), 137.05 (C-6), 150.97 
(C-2), 158.82 (NHCONH), 164.47 (C-4); HRMS (ESI-MS) for C23H32N6O9Na M + Na+: 
found, 559.2121; calcd, 559.2128. Anal. (C23H32N6O9) C, H, N. 
1-(3-Aminomethyl-3-deoxy-5-O-trityl--D-ribofuranosyl)thymine (24). Compound 15 
(450 mg, 0.83 mmol) and triphenylphosphine (356 mg, 1.36 mmol) were dissolved in 
pyridine (10 mL) and stirred at room temperature. After 1h concentrated NH4OH (8.5 mL) 
was added, and the solution was allowed to stir for an additional 2h. Pyridine was removed 
under reduced pressure, water (5 mL) was added, and the unreacted triphenylphosphine and 
triphenylphosphine oxide were removed by filtration. The filtrate was extracted with toluene, 
and the water layer was evaporated under reduced pressure to give a syrup. The syrup was 
purified by column chromatography (0.175 N NH3 in CH2Cl2-MeOH, 90:10) to yield the title 
compound (415 mg, 97 %) as a white foam. 1H NMR (300 MHz, DMSO-d6):  1.37 (3H, s, 5-
CH3), 2.25 (1H, m, H-3'), under DMSO signal (1H, H-5'), 2.67 (1H, dd, J = 7.8 and 12.6 Hz, 
H-5''), 3.18 (1H, dd, J = 4.5 and 10.5 Hz, H-6'), under H2O signal (1H, H-6''), 4.04 (1H, d, J = 
7.8 Hz, H-4'), 4.30 (1H, d, J = 5.4 Hz, H-2'), 5.64 (1H, s, H-1'), 7.33 (15H, m, arom H), 7.54 
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(1H, s, H-6); HRMS (ESI-MS) for C30H31N3O5Na M + Na+: found, 536.2162; calcd, 
536.2161. 
1-3-Aminomethyl-3-deoxy-2-O,6-N-(thiocarbonyl)-5-O-trityl--D-
ribofuranosylthymine (25). A solution of amine 24 (200 mg, 0.39 mmol) and 
thiocarbonyldiimidazole (78 mg, 0.43 mg) in THF (6 mL) was stirred overnight. The solvent 
was removed under reduced pressure and the obtained residue was purified by column 
chromatography (CH2Cl2-MeOH, 95:5) to yield 25 as a white powder (162 mg, 75 %). 1H 
NMR (300 MHz, DMSO-d6):  1.44 (3H, d, J = 1.2 Hz, 5-CH3), 2.90 (1H, d, J6', 6'' = 13.8 Hz, 
H-6'), 3.02 (1H, m, H-3'), H-5’ hidden by residual H2O signal, 3.38 (1H, dd, J5”, 4' = 3.0 Hz, 
J5”, 5’' = 11.7 Hz, H-5”), 3.46 (1H, dd, J6'', 3' = 5.4 Hz, J6”, 6’' = 13.8 Hz, H-6''), 3.99 (1H, dt, J = 
4.2 and 10.5 Hz, H-4'), 5.07 (1H, d, J2', 3' = 5.7 Hz, H-2'), 5.80 (1H, d, J = 0.9 Hz, H-1'), 7.33 
(15H, m, arom H), 7.53 (1H, s, H-6), 9.83 (1H, s, 6’-NH), 11.48 (1H, s, N(3)H); HRMS (ESI-
MS) for C31H29N3O5SNa M + Na+: found, 578.1825; calcd, 578.1725.  
1-3-Aminomethyl-3-deoxy-2-O,N-(thiocarbonyl)--D-ribofuranosylthymine (10) from 
25. Compound 24 (148 mg, 0.26 mmol) was dissolved in 80% HOAc in H2O (6mL). The 
mixture was heated to 90 °C during 1h. The solvent was removed under reduced pressure and 
the residue purified by column chromatography (CH2Cl2-MeOH, 90:10) yielding 10 (69 mg, 
85%) as a white powder. For characterization data: see above. 
1-[3-(Azidomethyl)-2,3-dideoxy--D-erythro-pentofuranosyl]thymine (13). -Anomer 13 
was a minor unreported byproduct from the synthesis of 1. 9 1H NMR (300 MHz, DMSO-d6): 
 1.76 (3H, d, 5-CH3), 1.80 (1H, m, H-2'), 2.25 (1H, ddd, J = 5.6, 7.0 and 12.3 Hz, H-2''), 2.73 
(1H, m, H-3'), 3.50-3.67 (4H, m, H-5'/5” and H-6'/6”), 4.02 (1H, dt, J = 3.9 and 8.1 Hz, H-4'), 
5.06 (1H, t, 5'-OH), 5.99 (1H, dd, J = 5.7 and 8.7 Hz, H-1'), 7.83 (1H, d, H-6), 13C NMR (75 
MHz, DMSO-d6):  12.95 (5-CH3), 35.46 (C-2'), 39.43 (C-3'), 51.03 (C-6'), 61.68 (C-5'), 
80.00 and 84.23 (C-1' and C-4'), 109.98 (C-5), 136.77 (C-6), 151.17 (C-2), 164.39 (C-4); 
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HRMS (ESI-MS) for C11H16N5O4 M + H+: found, 282.1205; calcd, 282.1202. Anal. 
(C11H15N5O4) C, H, N. 
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Table 1. Kinetic parameters of TMPKmt and TMPKh with compounds 1-13.  
R2
O
R3
N N
O
O
R1  
Compound 
 
R1 R2 R3 Ki (M) 
TMPKmt 
Ki (M) 
TMPKh 
SI (Ki TMPKh/ 
Ki TMPKmt) 
dTMP H OH OPO32- 4.5a 5.0a 1.1a
thymidine H OH OH 277 1808 6.6 
1 H CH2N3 OH 409 10409 26.0 
2 H CH2NH2 OH 579 2209 3.9 
3 F OH OPO32- 435 n. d. n. d. 
4 Cl OH OPO32- 195 n. d. n. d. 
5 Cl CH2N3 OH 180 n. d. n. d. 
6 Cl CH2NH2 OH 390 n. d. n. d. 
7 F CH2N3 OH 165 n. d. n. d. 
8 F CH2NH2 OH n.i. at 1 mM n. d. n. d. 
9 F CH2N3 F 80 n. d. n. d. 
10 2'-OC(S)NHCH2-3' OH 3.5  700 200.0 
11 2'-OC(O)NHCH2-3' OH 13.5 1100 81.5 
12 scheme 2 OH 37 n.i. at 1mM n. d. 
13b H CH2N3 OH 29 n.i.at 2 mM n. d. 
a Km-value; b Thymine is oriented at the -side of the sugar ring. 
n.i. no inhibition; n.d. not determined 
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 FIGURE LEGENDS 
Figure 1. Comparison of the binding mode of dTMP with the binding mode of compound 
12.  a) dTMP as observed in the X-ray structure with TMPKmt.4 b) Predicted 
binding mode of 12 with TMPKmt. Hydrogen bonds (based on distance) are 
drawn as dashed lines from 12 to residues Asp9, Arg14, Asn100 and Glu166. 
Residues of which atoms make hydrophobic contact with 12, based on the ligplot 
analysis are Lys13, Ala35, Tyr39, Phe36, Phe70, Arg95, Asn100, Tyr103 and 
Tyr165. 
 
Figure 2.  Predicted binding mode of 13 with TMPKmt. Possible hydrogen bonds are drawn 
as dashed lines with residues Asp9, Arg74 and Asn100. Residues of which atoms 
make hydrophobic contact with 13, based on a ligplot analysis, are Leu52, phe70, 
Arg95, Tyr103 and Tyr165.  
  
Figure 3.  Predicted binding mode of 10 with TMPKmt.  Hydrogen bonds are drawn as 
dashed lines involving residues Asp9, Asn100 and Arg74. Residues of which 
atoms make hydrophobic contact with 10, based on a Ligplot analysis, are Phe36, 
Pro37, Leu52, Phe70, Arg95, Tyr103 and Tyr165.  
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Reagents: (a) trityl chloride, DMAP, pyridine; (b) trifluoromethanesulfonyl chloride, DMAP, 
CH2Cl2; (c) HCl, dioxane; (d) Ph3P, NH4OH, pyridine; (e) NaOH, EtOH, H2O; (f) DAST, 
toluene, pyridine; (g) 80% HOAc in H2O. 
. 
 
 32
Scheme 2 
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Reagents: (a) t-butyldimethylsilyl chloride, AgNO3, pyridine, THF; (b) phenyl 
chlorothionocarbonate, DMAP, CH3CN; (c) AIBN, Bu3SnH, toluene; (d) n-Bu4NF, THF; (e) 
Ph3P, NH4OH, pyridine; (f) 1,1-thiocarbonyldiimidazole, DMF; (g) 80% HOAc in H2O. 
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Elemental analysis: 
 Calculated Found 
 C H N C H N 
5 41.85 4.47 22.18 41.78 4.81 21.74 
6 + H2O 42.93 5.90 13.65 42.68 5.98 13.31 
7 44.15 4.72 23.40 44.14 4.96 23.04 
8 + H2O 45.36 6.23 14.43 45.39 6.01 14.10 
9 46.00 4.83 13.41 45.67 4.84 13.21 
10  43.86 4.35 23.25 43.74 4.32 23.16 
11 48.49 5.09 14.14 48.61 5.31 13.92 
12 51.49 6.01 15.66 51.48 5.78 15.34 
13 46.97 5.38 24.90 46.95 5.24 24.63 
 
 
 
 
 
 
